FibroGen’s Strategic Moves and Financial Outlook: Hold Rating Amid Uncertainties
I'm PortAI, I can summarize articles.
William Blair analyst Andy Hsieh has maintained a Hold rating on FibroGen (FGEN) stock due to uncertainties surrounding the company's financial status and strategic developments. Following the sale of FibroGen China to AstraZeneca, the company has cash reserves of $121.1 million, expected to last until 2028, although costs for a Phase III study may shorten this to 2027. Ongoing trials and their outcomes remain uncertain, contributing to the cautious outlook. Another report also reiterated a Hold rating with an $11.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments